direct cell reprogramming using transcription-factor network analysis
Very little changed between August 2018 and January 2019. Mogrify described direct cell reprogramming the same way in both snapshots: a process that can be modeled, predicted, and steered by identifying the transcription factors with the strongest control over cell-state change. The core claim stayed stable: cell conversion is not treated as guesswork, it is framed as a computationally searchable problem in regulatory biology. The January 2019 version adds a bit more operational detail. It leans harder into what a user can do with the platform, namely explore candidate experiments, factor combinations, and regulatory-network changes across human cell types. That is an expansion in product framing, not a scientific pivot. The underlying belief still centers on transcription-factor network analysis as the engine for systematic reprogramming. Evidence is thin because we only have two website snapshots, five months apart, and both are polished company descriptions rather than technical retrospectives or admissions of failure. So the clean read is continuity: the message became slightly more explicit about workflow and use cases, but the belief itself barely moved.